Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BYSI BeyondSpring	$1.76	$2.23	$0.98 ▼ $3.44	$70.99M	0.26	27,658 shs	26,529 shs
FHTX Foghorn Therapeutics	$5.56 +10.3%	$5.26	$2.94 ▼ $10.25	$284.91M	3.05	102,469 shs	160,364 shs
NGNE Neurogene	$19.99 +1.2%	$20.28	$6.88 ▼ $74.49	$281.87M	1.69	117,183 shs	134,937 shs
RNAC Cartesian Therapeutics	$11.23 +2.5%	$11.67	$8.46 ▼ $26.50	$284.98M	0.44	52,936 shs	84,147 shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BYSI BeyondSpring	0.00%	-12.87%	-5.88%	+1.79%	-6.88%
FHTX Foghorn Therapeutics	+10.32%	+11.65%	-14.06%	+34.30%	-24.86%
NGNE Neurogene	+1.22%	-2.54%	-13.43%	+15.68%	-44.22%
RNAC Cartesian Therapeutics	+2.46%	-0.88%	-16.13%	+22.60%	-24.53%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BYSI BeyondSpring	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
FHTX Foghorn Therapeutics	2.3164 of 5 stars	3.6	3.0	0.0	0.0	0.6	1.7	0.6
NGNE Neurogene	1.7297 of 5 stars	3.4	0.0	0.0	0.0	2.1	1.7	0.6
RNAC Cartesian Therapeutics	2.5621 of 5 stars	3.4	2.0	0.0	0.0	2.4	3.3	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BYSI BeyondSpring	0.00	N/A	N/A	N/A
FHTX Foghorn Therapeutics	3.17	Buy	$10.67	91.85% Upside
NGNE Neurogene	2.75	Moderate Buy	$46.17	130.95% Upside
RNAC Cartesian Therapeutics	2.80	Moderate Buy	$40.00	256.19% Upside

Current Analyst Ratings Breakdown

Latest BYSI, RNAC, NGNE, and FHTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/9/2025	RNAC Cartesian Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$38.00
6/17/2025	NGNE Neurogene	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$50.00
6/12/2025	NGNE Neurogene	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$22.00 ➝ $26.00

(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BYSI BeyondSpring	$1.75M	40.56	N/A	N/A	($0.44) per share	-4.00
FHTX Foghorn Therapeutics	$24.17M	13.00	N/A	N/A	($1.36) per share	-4.09
NGNE Neurogene	$930K	306.73	N/A	N/A	$19.15 per share	1.04
RNAC Cartesian Therapeutics	$38.91M	7.50	N/A	N/A	($0.10) per share	-112.30

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BYSI BeyondSpring	-$11.12M	N/A	0.00	∞	N/A	N/A	N/A	N/A	11/6/2025 (Estimated)
FHTX Foghorn Therapeutics	-$86.62M	-$1.19	N/A	N/A	N/A	-311.90%	N/A	-28.00%	11/3/2025 (Estimated)
NGNE Neurogene	-$75.14M	-$4.31	N/A	N/A	N/A	N/A	-33.33%	-30.34%	N/A
RNAC Cartesian Therapeutics	-$77.42M	-$52.83	N/A	N/A	N/A	N/A	N/A	-6.36%	11/6/2025 (Estimated)

Latest BYSI, RNAC, NGNE, and FHTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	BYSI BeyondSpring	N/A	-$0.04	N/A	-$0.04	N/A	N/A
8/11/2025	Q2 2025	NGNE Neurogene	-$1.15	-$1.05	+$0.10	-$1.05	N/A	N/A
8/7/2025	Q2 2025	RNAC Cartesian Therapeutics	-$0.76	$0.50	+$1.26	$0.50	$0.77 million	$0.30 million
8/5/2025	Q2 2025	FHTX Foghorn Therapeutics	-$0.31	-$0.28	+$0.03	-$0.28	$7.62 million	$7.56 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BYSI BeyondSpring	N/A	N/A	N/A	N/A	N/A
FHTX Foghorn Therapeutics	N/A	N/A	N/A	N/A	N/A
NGNE Neurogene	N/A	N/A	N/A	N/A	N/A
RNAC Cartesian Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BYSI BeyondSpring	N/A	2.19	2.19
FHTX Foghorn Therapeutics	N/A	2.62	2.62
NGNE Neurogene	N/A	18.07	18.07
RNAC Cartesian Therapeutics	N/A	13.33	13.33

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BYSI BeyondSpring	40.29%
FHTX Foghorn Therapeutics	61.55%
NGNE Neurogene	52.37%
RNAC Cartesian Therapeutics	86.95%

Insider Ownership

Company	Insider Ownership
BYSI BeyondSpring	29.31%
FHTX Foghorn Therapeutics	7.58%
NGNE Neurogene	11.64%
RNAC Cartesian Therapeutics	60.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BYSI BeyondSpring	80	40.33 million	28.51 million	Optionable
FHTX Foghorn Therapeutics	120	56.53 million	52.25 million	Optionable
NGNE Neurogene	90	14.27 million	12.61 million	Optionable
RNAC Cartesian Therapeutics	64	26.00 million	10.32 million	Optionable

BYSI, RNAC, NGNE, and FHTX Headlines

Recent News About These Companies

Mizuho Securities Reaffirms Their Buy Rating on Cartesian Therapeutics (RNAC)

August 15, 2025 | theglobeandmail.com

BTIG Reaffirms Their Buy Rating on Cartesian Therapeutics (RNAC)

August 14, 2025 | theglobeandmail.com

Oppenheimer Sticks to Their Hold Rating for Cartesian Therapeutics (RNAC)

August 14, 2025 | theglobeandmail.com

Cartesian (RNAC) Q2 Revenue Drops 99%

August 9, 2025 | theglobeandmail.com

Cartesian Therapeutics Reports Positive Q2 2025 Earnings

August 8, 2025 | tipranks.com

Cartesian Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

August 7, 2025 | taiwannews.com.twT

Cartesian Therapeutics (RNAC) to Release Quarterly Earnings on Thursday

August 7, 2025 | marketbeat.com

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Receives Consensus Recommendation of "Moderate Buy" from Analysts

August 4, 2025 | marketbeat.com

Cartesian Therapeutics, Inc. (RNAC) Moves 9.9% Higher: Will This Strength Last?

July 24, 2025 | zacks.com

Wedbush Initiates Coverage of Cartesian Therapeutics (RNAC) with Outperform Recommendation

July 9, 2025 | msn.com

We're Not Very Worried About Cartesian Therapeutics' (NASDAQ:RNAC) Cash Burn Rate

June 21, 2025 | finance.yahoo.com

Cartesian Therapeutics holds annual stockholders meeting

June 17, 2025 | investing.com

Cartesian Therapeutics Announces New Employment Inducement Grants

June 3, 2025 | globenewswire.com

BTIG Sticks to Their Buy Rating for Cartesian Therapeutics (RNAC)

June 2, 2025 | theglobeandmail.com

Cartesian Therapeutics Announces First Participant Enrolled in the Phase 3 AURORA Trial of Descartes-08 in Patients with Myasthenia Gravis

May 30, 2025 | globenewswire.com

Cartesian Therapeutics to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ

May 13, 2025 | manilatimes.netM

Analysts Are Bullish on Top Healthcare Stocks: Harrow Health (HROW), Cartesian Therapeutics (RNAC)

May 11, 2025 | theglobeandmail.com

Cartesian Therapeutics (RNAC) Gets a Buy from Mizuho Securities

May 11, 2025 | theglobeandmail.com

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates

May 11, 2025 | finance.yahoo.com

Cartesian Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 8, 2025 | globenewswire.com

Why Cartesian Therapeutics, Inc. (RNAC) is Among the Best Small Cap Stocks to Buy with the Biggest Upside Potential

May 5, 2025 | insidermonkey.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BYSI, RNAC, NGNE, and FHTX Company Descriptions

BeyondSpring NASDAQ:BYSI

$1.76 0.00 (0.00%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$1.74 -0.01 (-0.85%)

As of 08/22/2025 07:59 PM Eastern

BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy or radiation, including; nivolumab, a PD-1 antibody that is has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey.

Foghorn Therapeutics NASDAQ:FHTX

$5.56 +0.52 (+10.32%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$5.60 +0.05 (+0.81%)

As of 08/22/2025 05:50 PM Eastern

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM that is in phase I for the treatment of relapsed and/or refractory acute myeloid leukemia/myelodysplastic syndrome. The company is also developing therapies for mutant cancers, such as Non-Small Cell Lung, bladder, endometrial, colorectal, and melanoma cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Neurogene NASDAQ:NGNE

$19.99 +0.24 (+1.22%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$19.90 -0.09 (-0.45%)

As of 08/22/2025 07:50 PM Eastern

Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC. The company is headquartered in New York, New York.

Cartesian Therapeutics NASDAQ:RNAC

$11.23 +0.27 (+2.46%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$11.19 -0.04 (-0.36%)

As of 08/22/2025 05:18 PM Eastern

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases. Cartesian Therapeutics, Inc. is headquartered in Gaithersburg, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time